JP2024534157A5 - - Google Patents
Info
- Publication number
- JP2024534157A5 JP2024534157A5 JP2024513011A JP2024513011A JP2024534157A5 JP 2024534157 A5 JP2024534157 A5 JP 2024534157A5 JP 2024513011 A JP2024513011 A JP 2024513011A JP 2024513011 A JP2024513011 A JP 2024513011A JP 2024534157 A5 JP2024534157 A5 JP 2024534157A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- modified
- nucleic acid
- modified oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163237898P | 2021-08-27 | 2021-08-27 | |
| US63/237,898 | 2021-08-27 | ||
| PCT/US2022/075493 WO2023028575A2 (en) | 2021-08-27 | 2022-08-26 | Compounds and methods for modulating scn1a expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534157A JP2024534157A (ja) | 2024-09-18 |
| JP2024534157A5 true JP2024534157A5 (enExample) | 2025-09-02 |
Family
ID=85322277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513011A Pending JP2024534157A (ja) | 2021-08-27 | 2022-08-26 | Ｓｃｎ１ａ発現を調節するための化合物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240360449A1 (enExample) |
| EP (1) | EP4392562A4 (enExample) |
| JP (1) | JP2024534157A (enExample) |
| KR (1) | KR20240049349A (enExample) |
| CN (1) | CN118451183A (enExample) |
| AU (1) | AU2022334739A1 (enExample) |
| CA (1) | CA3230299A1 (enExample) |
| IL (1) | IL310811A (enExample) |
| MX (1) | MX2024002553A (enExample) |
| WO (1) | WO2023028575A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020227825B2 (en) | 2019-02-27 | 2026-03-26 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
| CN115867657A (zh) | 2020-05-11 | 2023-03-28 | 斯托克制药公司 | 用于治疗疾患和疾病的opa1反义寡聚物 |
| CN116334086A (zh) * | 2023-03-29 | 2023-06-27 | 广州医科大学附属第二医院 | 一种用于修复或抑制SCN1A基因异常剪接的U1-snRNA及其用途 |
| CN121969747A (zh) * | 2023-07-24 | 2026-05-01 | 斯托克治疗公司 | 用于治疗疾患和疾病的方法 |
| WO2026052819A1 (en) * | 2024-09-06 | 2026-03-12 | Ospedale San Raffaele S.R.L. | Gene therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102318434B1 (ko) * | 2017-08-25 | 2021-11-01 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| JP2022537581A (ja) * | 2019-06-21 | 2022-08-26 | クラリス コーポレーション | Ｐｐｍ１阻害剤およびその使用方法 |
| KR20220062517A (ko) * | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | 결합 변형된 올리고머 화합물 및 이의 용도 |
| BR112022010882A2 (pt) * | 2019-12-06 | 2022-10-04 | Stoke Therapeutics Inc | Oligômeros antissenso para tratamento de condições e doenças |
| EP4110919A4 (en) * | 2020-02-28 | 2024-06-05 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION |
-
2022
- 2022-08-26 JP JP2024513011A patent/JP2024534157A/ja active Pending
- 2022-08-26 EP EP22862285.8A patent/EP4392562A4/en active Pending
- 2022-08-26 US US18/685,362 patent/US20240360449A1/en active Pending
- 2022-08-26 CN CN202280065211.6A patent/CN118451183A/zh active Pending
- 2022-08-26 CA CA3230299A patent/CA3230299A1/en active Pending
- 2022-08-26 MX MX2024002553A patent/MX2024002553A/es unknown
- 2022-08-26 WO PCT/US2022/075493 patent/WO2023028575A2/en not_active Ceased
- 2022-08-26 KR KR1020247009728A patent/KR20240049349A/ko active Pending
- 2022-08-26 AU AU2022334739A patent/AU2022334739A1/en active Pending
- 2022-08-26 IL IL310811A patent/IL310811A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024534157A5 (enExample) | ||
| US10487105B2 (en) | Trinucleotide MRNA cap analogs | |
| JP2021512629A5 (enExample) | ||
| CA3098624A1 (en) | Oligonucleotide compositions and methods of use thereof | |
| CN114025848A (zh) | 用于调节剪接和翻译的方法和组合物 | |
| JP2020193199A5 (enExample) | ||
| CA2936712A1 (en) | Chiral design | |
| CN114645048A (zh) | 用于治疗病况和疾病的反义寡聚体 | |
| JP2021522862A (ja) | ７’−５’−アルファ−アノマー二環式糖ヌクレオシドを含むオリゴヌクレオチドコンジュゲート | |
| EA022429B1 (ru) | АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ | |
| JP2019529489A5 (enExample) | ||
| JP2022527105A5 (enExample) | ||
| JP2022050389A (ja) | 一本鎖オリゴヌクレオチド | |
| JP7660515B2 (ja) | 病態及び疾患の治療用アンチセンスオリゴマー | |
| JP2023536994A5 (enExample) | ||
| JP2020511155A5 (enExample) | ||
| JP2021515784A (ja) | 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法 | |
| TW201840848A (zh) | 單股寡核苷酸 | |
| JP2024541771A5 (enExample) | ||
| TW202309283A (zh) | 反義寡核苷酸及其用於治療神經變性障礙之用途 | |
| JP2024540537A5 (enExample) | ||
| JP2025511394A (ja) | α４β１／７インテグリンリガンドコンジュゲート化合物及びその使用 | |
| JP2025510339A5 (enExample) | ||
| JP2023532518A5 (enExample) | ||
| TW202233578A (zh) | Ｔ型鈣離子通道調節劑及其使用方法 |